JPMorgan Upgrades G1 Therapeutics (GTHX) to Neutral
Tweet
Share
E-mailGet Alerts GTHX Hot Sheet
Price: $7.15 --0%
Rating Summary:
5 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 7 | New: 64
Rating Summary:
5 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 7 | New: 64
Join SI Premium – FREE
JPMorgan analyst Anupam Rama upgraded G1 Therapeutics (NASDAQ: GTHX) from Underweight to Neutral with a price target of $7.15.
For an analyst ratings summary and ratings history on G1 Therapeutics click here. For more ratings news on G1 Therapeutics click here.
Shares of G1 Therapeutics closed at $4.25 yesterday.
You May Also Be Interested In
- Morgan Stanley Upgrades Coloplast A/S (COLOB:DC) (CLPBY) to Equalweight
- BofA Securities Upgrades Timken (TKR) to Buy, 'Early innings of a transformation story'
- RBC Capital Upgrades OGE Energy (OGE) to Outperform
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
